基于WHO/HAI标准调查方法的武汉市骨质疏松治疗药物的可获得性及可负担性分析

doi:10.5246/jcps.2023.05.035

中国药学(英文版) ›› 2023, Vol. 32 ›› Issue (5): 417-425.DOI: 10.5246/jcps.2023.05.035

• 【药事管理与临床药学专栏】 • 上一篇下一篇

基于WHO/HAI标准调查方法的武汉市骨质疏松治疗药物的可获得性及可负担性分析

万敏¹, 刘金玉², 喻光燚¹, 童绥菊¹, 柯磊³, 张玉³, 游如旭³^,^*()

1. 武汉市东西湖区人民医院药剂科, 湖北武汉 430040
2. 华中科技大学同济医学院附属同济医院药学部, 湖北武汉 430022
3. 华中科技大学同济医学院附属协和医院药学部, 湖北武汉 430022

收稿日期:2022-09-06 修回日期:2022-11-29 接受日期:2022-12-08 出版日期:2023-06-02 发布日期:2023-06-02
通讯作者: 游如旭
作者简介:
+ Tel.: +86-27-85726937, E-mail: youruxu2008@163.com

Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method

Min Wan¹, Jinyu Liu², Guangyi Yu¹, Suiju Tong¹, Lei Ke³, Yu Zhang³, Ruxu You³^,^*()

1 Department of Pharmacy, People’s Hospital of Dongxihu District, Wuhan 430040, Hubei, China
2 Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China
3 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China

Received:2022-09-06 Revised:2022-11-29 Accepted:2022-12-08 Online:2023-06-02 Published:2023-06-02
Contact: Ruxu You

摘要/Abstract

摘要：

本研究分析了武汉市骨质疏松治疗药物的使用情况, 可为相关政策的制定提供参考。研究采用WHO/HAI标准化法, 对武汉市骨质疏松治疗药物进行调研, 并收集药品信息进行统计分析, 对可获得性和可负担性进行评价。结果显示, 在可获得性方面, 双膦酸盐类、活性维生素D及其类似物的可获得性相对较高; 地舒单抗、鲑降钙素以及特立帕肽可获得性一般; 依降钙素、雷洛昔芬及雷奈酸锶可获得性较低。在可负担性方面, 阿仑膦酸仿制药的可负担性较好, 其余10种骨质疏松治疗药物的可负担性均较差。研究表明, 武汉市骨质疏松治疗药物的总体可获得性一般, 并且可负担性较差。随着中国老龄化问题的加剧, 相关部门可考虑将更多种类的骨质疏松治疗药物纳入医保目录以及集中带量采购工作中, 进一步提高骨质疏松治疗药物的可获得性和可负担性。

关键词: WHO/HAI, 骨质疏松治疗药物, 可获得性, 可负担性

Abstract:

In the present study, we aimed to investigate the availability and affordability of osteoporosis (OP) treatment drugs in Wuhan and provide references for policymakers. We used the WHO/HAI standardization method to investigate the OP drug in Wuhan and collected drug information for statistical analysis to evaluate the availability and affordability. The results showed that the availability of bisphosphonates, active vitamin D, and their analogs was relatively high; the availability of denosumab, salmon calcitonin, and teriparatide was general; and the availability of calcitonin, raloxifene, and strontium ranelate was low. In terms of affordability, alendronate generic drugs had good affordability, while the other 10 OP treatment drugs had poor affordability. Generally, the overall availability of OP treatment drugs in Wuhan was average, and the affordability was poor. As China’s aging problem intensified, relevant government departments might consider including more OP treatment drugs in the medical insurance catalog and concentrating their quantities in the procurement process to further improve the availability and affordability of OP treatment drugs.

Key words: WHO/HAI, Osteoporosis treatment drugs, Availability, Affordability

Supporting:

万敏, 刘金玉, 喻光燚, 童绥菊, 柯磊, 张玉, 游如旭. 基于WHO/HAI标准调查方法的武汉市骨质疏松治疗药物的可获得性及可负担性分析[J]. 中国药学(英文版), 2023, 32(5): 417-425.

Min Wan, Jinyu Liu, Guangyi Yu, Suiju Tong, Lei Ke, Yu Zhang, Ruxu You. Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method[J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(5): 417-425.

图/表 6

Table 1. Specifications and dosage forms of 11 OP treatment drugs.

Table 2. The availability of OP treatment drugs (%).

Table 3. The availability of OP treatment drugs in public medical institutions and retail pharmacies (n = 11).

Table 4. Affordability of OP treatment drugs (unit: times).

Table 5. Comparison of the overall affordability of OP treatment drugs in public hospitals and retail pharmacies.

Table 6. Comparison of overall affordability of OBs and LPGs.

参考文献 24

[1]	Consensus development conference: prophylaxis and treatment of osteoporosis. Am. J. Med. 1991, 90, 107–110.
[2]	NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South. Med. J. 2001, 94, 569–573.
[3]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis (2017). Chin. J. Osteoporos. 2019, 25, 281–309.
[4]	Si, L.; Winzenberg, T.M.; Jiang, Q.; Chen, M.; Palmer, A.J. Projection of osteoporosis-related fractures and costs in China: 2010-2050. Osteoporos Int. 2015, 26, 1929–1937.
[5]	National Bureau of Statistics of the People's Republic of China. China Statistical Yearbook. Beijing: China Statistics Press. 2020.
[6]	Chinese Society of Osteoporosis and Bone Mineral Research. Guidelines for the diagnosis and management of primary osteoporosis. Chin. J. Osteoporos. 2019, 25, 281–309.
[7]	Kheder, S.; Ali, H.M. Medicine prices, availability, affordability and price components in Sudan. World Health Organization. 2014.
[8]	Zhang, Y.; Li, X. Investigation and analysis of availability and affordability of essential medicine in Nanjing based on WHO/HAI standard survey method. China Pharm. 2015, 26, 4188–4192.
[9]	Wang, X.; Yang, S.M.; Fang, Y.; Jiang, M.H.; Wu, L.N. Study on the availability and price of pediatric essential medicines in public hospitals in Shaanxi Province using WHO/HAI methodology. China Pharm. 2014, 25, 681–684.
[10]	Dong, Z.J.; Tao, Q.C.; Yan, B.B.; Sun, G.J. Availability, prices and affordability of essential medicines in Zhejiang Province, China. PLoS One. 2020, 15, e0241761.
[11]	Gong, S.W.; Cai, H.B.; Ding, Y.F.; Li, W.J.; Juan, X.; Peng, J.L.; Jin, S. The availability, price and affordability of antidiabetic drugs in Hubei Province, China. Health Policy Plan. 2018, 33, 937–947.
[12]	Department of Human Resources and Social Security of Hubei Province. Circular of the General Office of the Provincial People’s Government on Adjusting the Provincial Minimum Wage Standard. 2021 [EB/OL]. (2021-08-31). This article can be found online at http://www.hubei.gov.cn/zxjy/rdhy/202108/t20210831_3730793.shtml.
[13]	You, R.; Liu, Z. Economic evaluation of oral alendronate therapy for osteoporosis in Chinese postmenopausal women: the impact of medication compliance and persistence. Front. Pharmacol. 2020, 11, 575893.
[14]	You, R.; Zhang, Y.; Wu, D.B.; Liu, J.; Qian, X.; Luo, N.; Mori, T. Cost-effectiveness of zoledronic acid versus oral alendronate for postmenopausal osteoporotic women in China. Front. Pharmacol. 2020, 11, 456.
[15]	Eastell, R.; Rosen, C.J.; Black, D.M.; Cheung, A.M.; Murad, M.H.; Shoback, D. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society. J. Clin. Endocrinol. Metab. 2019, 104, 1595–1622.
[16]	Mori, T.; Crandall, C.J.; Ganz, D.A. Cost-effectiveness of combined oral bisphosphonate therapy and Falls prevention exercise for fracture prevention in the USA. Osteoporos. Int. 2017, 28, 585–595.
[17]	Mori, T.; Crandall, C.J.; Fujii, T.; Ganz, D.A. Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. Arch. Osteoporos. 2021, 16, 113.
[18]	Li, N.N.; Cornelissen, D.; Silverman, S.; Pinto, D.; Si, L.; Kremer, I.; Bours, S.; de Bot, R.; Boonen, A.; Evers, S.; van den Bergh, J.; Reginster, J.Y.; Hiligsmann, M. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. PharmacoEconomics. 2021, 39, 181–209.
[19]	Cosman, F.; Nieves, J.W.; Dempster, D.W. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J. Bone Miner. Res. 2017, 32, 198–202.
[20]	Mori, T.; Crandall, C.J.; Fujii, T.; Ganz, D.A. Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. Arch. Osteoporos. 2021, 16, 72.
[21]	Lv, F.B.; Yu, K.W.; Gao, W.W.; Yu, S.W. Cost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J. Chin. Pharm. Sci. 2017, 26, 447–454.
[22]	Chen, J.; Zhao L.B.; Wan Y.S.; Wang L.; Lv, Y.N.; Zhang, Y.; You, R.X. Rapid health technology assessment of treating osteoporosis with alendronate. Chin. J. Hospital Pharmacy. 2021, 41, 2227–2235.
[23]	Wang, H. Analysis on the principal component of the factors which effected medicine prices in China. Chin. Health Econ. 2018, 37, 71–73.
[24]	Luo, S.H.; Dong, L.L.; Li, Y.Y.; Xu, D.; Chen, M. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib, gefitinib, afatinib and osimertinib) as first-line therapy for epidermal growth factor receptor-mutated advanced non-small cell lung cancer. J. Chin. Pharm. Sci. 2021, 30, 253–263.

基于WHO/HAI标准调查方法的武汉市骨质疏松治疗药物的可获得性及可负担性分析

Availability and affordability of osteoporosis treatment drugs in Wuhan based on the WHO/HAI standard survey method

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 24

相关文章 0

编辑推荐

Metrics

本文评价